APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Conjugate Vaccine (PCV)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pneumococcal Conjugate Vaccine (PCV) Industry Growth and Trends Forecast to 2032

2 January 202685 pages

Choose your research edition.

Industry ResearchPneumococcal Conjugate Vaccine (PCV) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Conjugate Vaccine (PCV) Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Pneumococcal Conjugate Vaccine (PCV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Conjugate Vaccine (PCV) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Conjugate Vaccine (PCV) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

According to APO Research, the global Pneumococcal Conjugate Vaccine (PCV) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Pneumococcal Conjugate Vaccine (PCV) market include Sanofi, Merck, Pfizer, GSK, Zhifei Biologic, Walvax Biotechnology, Serum Institute of India and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pneumococcal Conjugate Vaccine (PCV) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pneumococcal Conjugate Vaccine (PCV) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pneumococcal Conjugate Vaccine (PCV) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pneumococcal Conjugate Vaccine (PCV).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Pneumococcal Conjugate Vaccine (PCV) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pneumococcal Conjugate Vaccine (PCV) Market by Company

Sanofi

Merck

Pfizer

GSK

Zhifei Biologic

Walvax Biotechnology

Serum Institute of India

Royal (Wuxi) Bio-Pharmaceutical

Pneumococcal Conjugate Vaccine (PCV) Segment by Type

10-valent Vaccine

13-valent Vaccine

23-valent Vaccine

7-valent Vaccine

Pneumococcal Conjugate Vaccine (PCV) Segment by Application

Child

Adult

Pneumococcal Conjugate Vaccine (PCV) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Conjugate Vaccine (PCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Conjugate Vaccine (PCV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Conjugate Vaccine (PCV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Pneumococcal Conjugate Vaccine (PCV) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2021-2026) Table 4. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2027-2032) Table 6. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Type (2021-2026) Table 9. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share Forecasted by Type (2027-2032) Table 11. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2021-2026) Table 24. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share Forecasted by Application (2027-2032) Table 26. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Pneumococcal Conjugate Vaccine (PCV) Industry Trends Table 37. Pneumococcal Conjugate Vaccine (PCV) Industry Drivers Table 38. Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges Table 39. Pneumococcal Conjugate Vaccine (PCV) Industry Restraints Table 40. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Company (2021-2026) Table 42. Global Pneumococcal Conjugate Vaccine (PCV) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Pneumococcal Conjugate Vaccine (PCV) Key Company Headquarters & Area Served Table 44. Global Pneumococcal Conjugate Vaccine (PCV) Company, Product Type & Application Table 45. Global Pneumococcal Conjugate Vaccine (PCV) Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Pneumococcal Conjugate Vaccine (PCV) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 52. Sanofi Recent Development Table 53. Merck Company Information Table 54. Merck Business Overview Table 55. Merck Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 57. Merck Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 62. Pfizer Recent Development Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 67. GSK Recent Development Table 68. Zhifei Biologic Company Information Table 69. Zhifei Biologic Business Overview Table 70. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 72. Zhifei Biologic Recent Development Table 73. Walvax Biotechnology Company Information Table 74. Walvax Biotechnology Business Overview Table 75. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 77. Walvax Biotechnology Recent Development Table 78. Serum Institute of India Company Information Table 79. Serum Institute of India Business Overview Table 80. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 82. Serum Institute of India Recent Development Table 83. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 84. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 85. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 87. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 88. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 90. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2026) Table 91. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. North America Pneumococcal Conjugate Vaccine (PCV) Market Share Forecast by Country (2027-2032) Table 93. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 95. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2026) Table 96. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share Forecast by Country (2027-2032) Table 98. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 100. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2026) Table 101. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Share Forecast by Country (2027-2032) Table 103. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 105. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2026) Table 106. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Share Forecast by Country (2027-2032) Table 108. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 110. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2026) Table 111. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share Forecast by Country (2027-2032) Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Pneumococcal Conjugate Vaccine (PCV) Product Image Figure 3. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 5. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region: 2025 VS 2032 Figure 6. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2021-2032) Figure 7. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. 10-valent Vaccine Image Figure 13. Global 10-valent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. 13-valent Vaccine Image Figure 15. Global 13-valent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. 23-valent Vaccine Image Figure 17. Global 23-valent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. 7-valent Vaccine Image Figure 19. Global 7-valent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Type 2025 VS 2032 Figure 22. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Type (2021-2032) Figure 23. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Type (2021-2032) Figure 25. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Type (2021-2032) Figure 27. Child Image Figure 28. Global Child Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Adult Image Figure 30. Global Adult Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Application 2025 VS 2032 Figure 33. North America Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2021-2032) Figure 34. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2021-2032) Figure 36. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Pneumococcal Conjugate Vaccine (PCV) Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 43. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 46. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 49. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 52. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • 10-valent Vaccine
  • 13-valent Vaccine
  • 23-valent Vaccine
  • 7-valent Vaccine
Applications
  • Child
  • Adult
Companies covered
  • Sanofi
  • Merck
  • Pfizer
  • GSK
  • Zhifei Biologic
  • Walvax Biotechnology
  • Serum Institute of India
  • Royal (Wuxi) Bio-Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2032)
  5. 1.4.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2026)
  6. 1.4.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2027-2032)
  7. 1.5 Key Regions Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
  8. 1.5.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (2021-2032)
2 Pneumococcal Conjugate Vaccine (PCV) Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 10-valent Vaccine
  3. 2.1.2 13-valent Vaccine
  4. 2.1.3 23-valent Vaccine
  5. 2.1.4 7-valent Vaccine
  6. 2.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type
  7. 2.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Pneumococcal Conjugate Vaccine (PCV) Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Regions
  11. 2.3.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Type (2021-2026)
3 Pneumococcal Conjugate Vaccine (PCV) Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Child
  3. 3.1.2 Adult
  4. 3.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application
  5. 3.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global Pneumococcal Conjugate Vaccine (PCV) Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Regions
  9. 3.3.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Pneumococcal Conjugate Vaccine (PCV) Industry Trends
  2. 4.2 Pneumococcal Conjugate Vaccine (PCV) Industry Drivers
  3. 4.3 Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges
  4. 4.4 Pneumococcal Conjugate Vaccine (PCV) Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Pneumococcal Conjugate Vaccine (PCV) Revenue (2021-2026)
  2. 5.2 Global Pneumococcal Conjugate Vaccine (PCV) Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Pneumococcal Conjugate Vaccine (PCV) Key Company Headquarters & Area Served
  4. 5.4 Global Pneumococcal Conjugate Vaccine (PCV) Company, Product Type & Application
  5. 5.5 Global Pneumococcal Conjugate Vaccine (PCV) Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Pneumococcal Conjugate Vaccine (PCV) Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Pneumococcal Conjugate Vaccine (PCV) Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Pneumococcal Conjugate Vaccine (PCV) Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Merck
  8. 6.2.1 Merck Company Information
  9. 6.2.2 Merck Business Overview
  10. 6.2.3 Merck Pneumococcal Conjugate Vaccine (PCV) Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  12. 6.2.5 Merck Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Pneumococcal Conjugate Vaccine (PCV) Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 Zhifei Biologic
  26. 6.5.1 Zhifei Biologic Company Information
  27. 6.5.2 Zhifei Biologic Business Overview
  28. 6.5.3 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  30. 6.5.5 Zhifei Biologic Recent Developments
  31. 6.6 Walvax Biotechnology
  32. 6.6.1 Walvax Biotechnology Company Information
  33. 6.6.2 Walvax Biotechnology Business Overview
  34. 6.6.3 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  36. 6.6.5 Walvax Biotechnology Recent Developments
  37. 6.7 Serum Institute of India
  38. 6.7.1 Serum Institute of India Company Information
  39. 6.7.2 Serum Institute of India Business Overview
  40. 6.7.3 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  42. 6.7.5 Serum Institute of India Recent Developments
  43. 6.8 Royal (Wuxi) Bio-Pharmaceutical
  44. 6.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  45. 6.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  46. 6.8.3 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  48. 6.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
7 North America
  1. 7.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  3. 7.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  3. 8.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  3. 10.3 South America Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst